UK IPFN paediatric candidiasis study
Research type
Research Study
Full title
Multi center studies to improve diagnosis and treatment of paediatric candidiasis
IRAS ID
171346
Contact name
Adilia Warris
Contact email
Sponsor organisation
The Childrens Hospital of Philadelphia
Duration of Study in the UK
2 years, 6 months, 30 days
Research summary
Invasive fungal infections are one of the leading causes of death in children with an impaired immune system. Children with cancer, children born with an inborn error of their immune system and children admitted to paediatric intensive care units are examples of children with an impaired immune system, and are at risk for developing invasive fungal infections. Candida (a fungus) is the most common fungus causing invasive infections in children. This study aims to compare the effectiveness of different antifungal drugs used to treat invasive candidiasis in children. Due to the fact that most studies done to establish the best treatment for invasive candida infections are performed in adults, we are not well enough informed about the best treatment strategy in children. This international multi-center observational study will collect clinical data from 600 children suffering from invasive candida infections treated with any of the 3 classes of antifungal drugs to treat invasive candida infections. It is expected that about 200 children will be treated with a specific class of an antifungal drug, and will give us the possibility to compare the effectiveness of those antifungal drugs. The results will give us an improved insight which antifungal or antifungals are the best choices to treat invasive candida infections in children.
REC name
North of Scotland Research Ethics Committee 2
REC reference
16/NS/0002
Date of REC Opinion
19 Feb 2016
REC opinion
Further Information Favourable Opinion